tacrolimus and Hepatopulmonary-Syndrome

tacrolimus has been researched along with Hepatopulmonary-Syndrome* in 1 studies

Other Studies

1 other study(ies) available for tacrolimus and Hepatopulmonary-Syndrome

Article	Year
Case report of unchanged tacrolimus clearance in a hypoxemic pediatric liver transplant recipient with hepatopulmonary syndrome. Transplant international : official journal of the European Society for Organ Transplantation, 2004, Volume: 17, Issue:10 Reductions in hepatic oxygen supply may reduce the oxidative metabolism of drugs, including tacrolimus. We encountered a patient (2.3-year-old girl) with hypoxemia [arterial oxygen tension (PaO2) 40.9 mmHg in room air] due to hepatopulmonary syndrome who had undergone living related liver transplantation. After transplantation, tacrolimus was initially administered by continuous intravenous infusion, and her PaO2 was maintained at more than 50 mmHg [72.8+/-10.4 (SD) mmHg] by oxygen supplementation. Apparent clearance of tacrolimus (calculated as: the infusion rate of tacrolimus/blood concentration) in the patient (0.075 l/h per kg) was comparable to those of non-hypoxemic control pediatric cases (0.092+/-0.014 l/h per kg, n=7, mean age 2.2 years, PaO2 149.2+/-41.5 mmHg), except for the acute decline in the early period after transplantation. These findings suggest that the reduction in tacrolimus clearance is negligible when arterial oxygen tension is maintained at more than 50 mmHg, even in patients with hypoxemia. Topics: Arteries; Case-Control Studies; Child, Preschool; Female; Hepatopulmonary Syndrome; Humans; Hypoxia; Immunosuppressive Agents; Infant; Infusions, Intravenous; Liver Transplantation; Male; Oxygen; Partial Pressure; Postoperative Period; Tacrolimus	2004

Article

Year

Case report of unchanged tacrolimus clearance in a hypoxemic pediatric liver transplant recipient with hepatopulmonary syndrome.

Transplant international : official journal of the European Society for Organ Transplantation, 2004, Volume: 17, Issue:10

Reductions in hepatic oxygen supply may reduce the oxidative metabolism of drugs, including tacrolimus. We encountered a patient (2.3-year-old girl) with hypoxemia [arterial oxygen tension (PaO2) 40.9 mmHg in room air] due to hepatopulmonary syndrome who had undergone living related liver transplantation. After transplantation, tacrolimus was initially administered by continuous intravenous infusion, and her PaO2 was maintained at more than 50 mmHg [72.8+/-10.4 (SD) mmHg] by oxygen supplementation. Apparent clearance of tacrolimus (calculated as: the infusion rate of tacrolimus/blood concentration) in the patient (0.075 l/h per kg) was comparable to those of non-hypoxemic control pediatric cases (0.092+/-0.014 l/h per kg, n=7, mean age 2.2 years, PaO2 149.2+/-41.5 mmHg), except for the acute decline in the early period after transplantation. These findings suggest that the reduction in tacrolimus clearance is negligible when arterial oxygen tension is maintained at more than 50 mmHg, even in patients with hypoxemia.

Topics: Arteries; Case-Control Studies; Child, Preschool; Female; Hepatopulmonary Syndrome; Humans; Hypoxia; Immunosuppressive Agents; Infant; Infusions, Intravenous; Liver Transplantation; Male; Oxygen; Partial Pressure; Postoperative Period; Tacrolimus

2004